• Explore /
  • Poster
  • / Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.

Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.

Abstract Poster

Authors

null

David Samuel DiCapua Siegel

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ

David Samuel DiCapua Siegel , Paul Gerard Guy Richardson , Ravi Vij , Craig C. Hofmeister , Rachid C. Baz , Sundar Jagannath , Christine Chen , Sagar Lonial , Andrzej J. Jakubowiak , Nizar J. Bahlis , Kevin W. Song , Andrew Belch , Noopur S. Raje , Chaim Shustik , Suzanne Lentzsch , Min Chen , Mohamed H. Zaki , Kenneth Carl Anderson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT00833833

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8588)

DOI

10.1200/jco.2013.31.15_suppl.8588

Abstract #

8588

Poster Bd #

54A

Abstract Disclosures

Similar Posters

First Author: Sundar Jagannath

First Author: Philippe Moreau

First Author: Cyrille Touzeau

First Author: Andrew Jenho Yee